Gastrointestinal Stromal Cell Tumors clinical trials at UCSD
1 research study open to eligible people
Showing trials for
Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
open to eligible people ages 18 years and up
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
La Jolla, California and other locations
Last updated: